1. Home
  2. CARR vs ARGX Comparison

CARR vs ARGX Comparison

Compare CARR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carrier Global Corporation

CARR

Carrier Global Corporation

HOLD

Current Price

$68.68

Market Cap

59.6B

Sector

Industrials

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$859.07

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CARR
ARGX
Founded
2019
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.6B
58.4B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
CARR
ARGX
Price
$68.68
$859.07
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$70.62
$1,008.56
AVG Volume (30 Days)
4.8M
353.9K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.55%
N/A
EPS Growth
N/A
N/A
EPS
0.28
N/A
Revenue
$21,747,000,000.00
N/A
Revenue This Year
$2.91
$44.39
Revenue Next Year
$5.37
$20.84
P/E Ratio
$247.39
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$50.24
$560.91
52 Week High
$81.09
$953.58

Technical Indicators

Market Signals
Indicator
CARR
ARGX
Relative Strength Index (RSI) 48.02 44.88
Support Level $65.77 $832.63
Resistance Level $76.76 $939.08
Average True Range (ATR) 2.10 22.42
MACD -0.42 -9.02
Stochastic Oscillator 33.67 14.65

Price Performance

Historical Comparison
CARR
ARGX

About CARR Carrier Global Corporation

Carrier Global, spun out of United Technologies in 2020, manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its flagship Carrier brand, as well as Bryant, Payne, Heil, and others across various price points. In 2024, Carrier acquired Viessmann Climate Solutions to expand its footprint in Europe with heat pumps, boilers, and solar PV equipment. Proceeds from the sale of Carrier's fire and security (Honeywell) and commercial refrigeration (Haier) businesses reduced debt and focused the company on global HVAC and refrigeration solutions. Carrier generates 75% of sales from equipment and 25% from parts and services. The company derives 50% of revenue from the US, 30% from Europe, and 20% from the Asia-Pacific region.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: